IP Library › Granted Patent US 7,611,721
Granted Patent B1
US 7,611,721 · App. 10/009,473 · Granted Nov 3, 2009

Adjuvant combination formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,611,721
App. No.
10/009,473
Granted
Nov 3, 2009
Kind
B1
Abstract

The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.

Claims (55)

1. An antigenic composition consisting of an antigen and an effective adjuvanting amount of the combination of: (1) 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A, and (2) granulocyte macrophage colony stimulating factor (GM-CSF), together with a diluent or carrier.

2. The antigenic composition of claim 1 , where the antigen is a polypeptide, peptide or fragment derived from a protein.

3. The antigenic composition of claim 1 , where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

4. The antigenic composition of claim 1 , where the antigen is derived from a pathogenic virus.

5. The antigenic composition of claim 1 , where the antigen is derived from a pathogenic bacterium.

6. The antigenic composition of claim 1 , where the antigen is derived from a pathogenic fungus.

7. The antigenic composition of claim 1 , where the antigen is derived from a pathogenic parasite.

8. The antigenic composition of claim 1 , where the antigen is derived from a cancer cell or tumor cell.

9. The antigenic composition of claim 1 , where the antigen is derived from an allergen.

10. The antigenic composition of claim 1 , where the antigen is derived from AP protein or peptide thereof, or an antibody thereto.

11. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic virus to elicit an immune response in a vertebrate host against said pathogenic virus, which comprises administering to said host an antigenic composition of claim 4 .

12. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic bacterium to elicit the immune response of a vertebrate host, which comprises administering to said host an antigenic composition of claim 5 .

13. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic fungus to elicit the immune response of a vertebrate host, which comprises administering to said host an antigenic composition of claim 6 .

14. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic parasite to elicit the immune response of a vertebrate host, which comprises administering to said host an antigenic composition of claim 7 .

15. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic virus to elicit cytotoxic T lymphocytes responses in a vertebrate host, which comprises administering to said host an antigenic composition of claim 4 .

16. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic bacterium to elicit cytotoxic T lymphocytes in a vertebrate host, which comprises administering to said host an antigenic composition of claim 5 .

17. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic fungus to elicit cytotoxic T lymphocytes in a vertebrate host, which comprises administering to said host an antigenic composition of claim 6 .

18. A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic parasite to elicit cytotoxic T lymphocytes in a vertebrate host, which comprises administering to said host an antigenic composition of claim 7 .

19. A method for increasing the ability of an antigenic composition containing a selected cancer antigen or tumor-associated antigen from a cancer cell or tumor cell to elicit a therapeutic or prophylactic anti-cancer effect in a vertebrate host, which comprises administering to said host an antigenic composition of claim 8 .

20. A method for increasing the ability of an antigenic composition containing a selected allergen to moderate an allergic response in a vertebrate host, which comprises administering to said host an antigenic composition of claim 9 .

21. A method for increasing the ability of an antigenic composition to prevent or treat disease characterized by amyloid deposition in a vertebrate host, which comprises administering to said host an antigenic composition of claim 10 .

22. The antigenic composition of claim 4 , where the antigen is from human immunodeficiency virus (HIV).

23. The antigenic composition of claim 22 , where the HIV antigen is an HIV protein, polypeptide, peptide or fragment derived from said protein.

24. The antigenic composition of claim 23 where the antigen is the HIV peptide having the amino acid sequence: Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:1), or Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

25. The antigenic composition of claim 22 , where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

26. The antigenic composition of claim 4 , where the antigen is from simian immunodeficiency virus (SIV).

27. The antigenic composition of claim 26 , where the SIV antigen is an SIV protein, polypeptide, peptide or fragment derived from said protein.

28. The antigenic composition of claim 27 , where the SIV peptide selected from the peptides consisting of the amino acid sequences: Cys Thr Pro Tyr Asp Ile Asn Gln Met (SEQ ID NO:3), Ser Thr Pro Pro Leu Val Arg Leu Val (SEQ ID NO:4), Tyr Ala Pro Pro Ile Ser Gly Gln Ile (SEQ ID NO:5), Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met (SEQ ID NO:7), Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Ser Thr Pro Pro Leu Val Arg Leu Val (SEQ ID NO:8) and Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Tyr Ala Pro Pro Ile Ser Gly Gln Ile (SEQ ID NO:9).

29. The antigenic composition of claim 26 , where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

30. The antigenic composition of claim 5 , where the antigen is from Neisseria gonorrhoeae.

31. The antigenic composition of claim 30 , where the Neisseria gonorrhoeae antigen is a Neisseria gonorrhoeae protein, polypeptide, peptide or fragment derived from said protein.

32. The antigenic composition of claim 31 , where the antigen is the Neisseria gonorrhoeae Porin B protein.

33. The antigenic composition of claim 30 , where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

34. The antigenic composition of claim 4 , where the antigen is from human Respiratory syncytial virus (RSV).

35. The antigenic composition of claim 34 , where the RSV antigen is an RSV protein, polypeptide, peptide or fragment derived from said protein.

36. The antigenic composition of claim 35 , where the antigen is the RSV fusion (F) protein.

37. The antigenic composition of claim 34 , where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

38. A method for increasing the ability of an antigenic composition containing an HIV antigen to elicit an immune response to said antigen in a vertebrate host, which comprises administering to said host an antigenic composition of claim 22 .

39. The method of claim 38 , where the HIV antigen is the HIV peptide having the amino acid sequence: Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:1).

40. The method of claim 38 , where the HIV antigen is the HIV peptide having the amino acid sequence: Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

41. A method for increasing the ability of an antigenic composition containing an HIV antigen to elicit cytotoxic T lymphocyte responses in a vertebrate host, which comprises administering to said host an antigenic composition of claim 22 .

42. The method of claim 41 , where the HIV antigen is the HIV peptide having the amino acid sequence: Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:1).

43. The method of claim 41 , where the HIV antigen is the HIV peptide having the amino acid sequence: Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

44. A method for increasing the ability of an antigenic composition containing an SIV antigen to elicit the immune response of a vertebrate host, which comprises administering to said host an antigenic composition of claim 26 .

45. The method of claim 44 , where the SIV antigen is an SIV peptide selected from the peptides consisting of the amino acid sequences: Cys Thr Pro Tyr Asp Ile Asn Gln Met (SEQ ID NO:3), Ser Thr Pro Pro Leu Val Arg Leu Val (SEQ ID NO:4), Tyr Ala Pro Pro Ile Ser Gly Gln Ile (SEQ ID NO:5), Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met (SEQ ID NO:7), Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Ser Thr Pro Pro Leu Val Arg Leu Val (SEQ ID NO:8) and Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Tyr Ala Pro Pro Ile Ser Gly Gln Ile (SEQ ID NO:9).

46. A method for increasing the ability of an antigenic composition containing an SIV antigen to elicit cytotoxic T lymphocytes in a vertebrate host, which comprises administering to said host an antigenic composition of claim 26 .

47. The method of claim 46 , where the SIV antigen is an SIV peptide selected from the peptides consisting of the amino acid sequences: Cys Thr Pro Tyr Asp Ile Asn Gln Met (SEQ ID NO:3), Ser Thr Pro Pro Leu Val Arg Leu Val (SEQ ID NO:4), Tyr Ala Pro Pro Ile Ser Gly Gln Ile (SEQ ID NO:5), Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met (SEQ ID NO:7), Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Ser Thr Pro Pro Leu Val Arg Leu Val (SEQ ID NO:8) and Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Tyr Ala Pro Pro Ile Ser Gly Gln Ile (SEQ ID NO:9).

48. A method for increasing the ability of an antigenic composition containing a Neisseria gonorrhoeae antigen to elicit the immune response of a vertebrate host, which comprises administering to said host an antigenic composition of claim 30 .

49. The method of claim 48 , where the Neisseria gonorrhoeae antigen is the Neisseria gonorrhoeae Porin B protein.

50. A method for increasing the ability of an antigenic composition containing a Neisseria gonorrhoeae antigen to elicit cytotoxic T lymphocytes in a vertebrate host, which comprises administering to said host an antigenic composition of claim 30 .

51. The method of claim 50 , where the Neisseria gonorrhoeae antigen is the Neisseria gonorrhoeae Porin B protein.

52. A method for increasing the ability of an antigenic composition containing a human Respiratory syncytial virus (RSV) antigen to elicit the immune response of a vertebrate host, which comprises administering to said host an antigenic composition of claim 34 .

53. The method of claim 52 , where the RSV antigen is the RSV fusion (F) protein.

54. A method for increasing the ability of an antigenic composition containing an RSV antigen to elicit cytotoxic T lymphocytes in a vertebrate host, which comprises administering to said host an antigenic composition of claim 34 .

55. The method of claim 54 , where the RSV antigen is the RSV fusion (F) protein.

Assignments (1)
MERGER Recorded May 13, 2015
From: ZOETIS WHC 2 LLC
To: ZOETIS SERVICES LLC
Reel/Frame 035623/0959 →